Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 14/20 | 0.57 |
| ▸ | NPC1 | O15118 | 12/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.54 |
| ▸ | MAPT | P10636 | 7/20 | 0.54 |
| ▸ | PKM | P14618 | 3/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.54 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.54 |
| ▸ | RELA | Q04206 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | TP53 | P04637 | 3/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | CASP3 | P42574 | 1/20 | 0.48 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5338102 | 0.85 | NPC1 (0.66) | RAB9ANPC1SMN1; SMN2MAPTPKM | |
| SCHEMBL5345438 | 0.85 | MAPT (0.58) | RAB9ANPC1SMN1; SMN2MAPTPKM | |
| SCHEMBL5335243 | 0.82 | NPC1 (0.63) | RAB9ANPC1SMN1; SMN2MAPTPKM | |
| SCHEMBL21934954 | 0.74 | RAB9A (0.53) | RAB9ANPC1SMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL27179668 | 0.73 | RAB9A (0.90) | RAB9ANPC1SMN1; SMN2MAPTPKM | |
| SCHEMBL30128152 | 0.72 | HPGD (0.54) | RAB9ANPC1SMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL18941082 | 0.72 | RAB9A (0.78) | RAB9ANPC1SMN1; SMN2MAPTPKM | |
| SCHEMBL13293301 | 0.72 | NPC1 (0.80) | RAB9ANPC1SMN1; SMN2MAPTPKM | |
| SCHEMBL108116 | 0.72 | NPC1 (1.00) | RAB9ANPC1SMN1; SMN2MAPTPKM | |
| SCHEMBL25765135 | 0.71 | KMT2A (0.49) | RAB9ANPC1SMN1; SMN2MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6995151-B2 | Isophthalic acid derivatives as matrix metalloproteinase inhibitors | WARNER-LAMBERT COMPANY (US) | 2006-02-07 | — | — | US | claimed |
| US-20020156061-A1 | Isophthalic acid derivatives as matrix metalloproteinase inhibitors | BARVIAN NICOLE CHANTEL (US) | 2002-10-24 | — | — | US | claimed |
| US-7214712-B2 | Isophthalic acid derivatives as matrix metalloproteinase inhibitors | WARNER-LAMBERT COMPANY (US) | 2007-05-08 | — | — | US | disclosed |
| US-6995151-B2 | Isophthalic acid derivatives as matrix metalloproteinase inhibitors | WARNER-LAMBERT COMPANY (US) | 2006-02-07 | — | — | US | disclosed |
| US-20060025396-A1 | Isophthalic acid derivatives as matrix metalloproteinase inhibitors | BARVIAN NICOLE C | 2006-02-02 | — | — | US | disclosed |
| US-20040019053-A1 | Combination of an allosteric carboxylic inhibitor of matrix metalloproteinase-13 with celecoxib or valdecoxib | ROARK WILLIAM HOWARD (US) | 2004-01-29 | — | — | US | disclosed |
| US-20040019054-A1 | Combination of an allosteric carboxylic inhibitor of matrix metalloproteinase-13 with a selective inhibitor of cyclooxygenase-2 that is not celecoxib or valdecoxib | ROARK WILLIAM HOWARD (US) | 2004-01-29 | — | — | US | disclosed |
| US-20020156061-A1 | Isophthalic acid derivatives as matrix metalloproteinase inhibitors | BARVIAN NICOLE CHANTEL (US) | 2002-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060025396-A1 | Isophthalic acid derivatives as matrix metalloproteinase inhibitors | MMP13, MMP11, MMP3 | RAB9A 3620/4885NPC1 1050/4885SMN1; SMN2 2320/4885 |
| US-20040019053-A1 | Combination of an allosteric carboxylic inhibitor of matrix metalloproteinase-13 with celecoxib or valdecoxib | MMP13, MMP11, MMP10 | RAB9A 1604/4885NPC1 3123/4885SMN1; SMN2 1550/4885 |
| US-20020156061-A1 | Isophthalic acid derivatives as matrix metalloproteinase inhibitors | MMP13, MMP1, MMP11 | RAB9A 3450/4885NPC1 297/4885SMN1; SMN2 1429/4885 |
| US-20040019054-A1 | Combination of an allosteric carboxylic inhibitor of matrix metalloproteinase-13 with a selective inhibitor of cyclooxygenase-2 that is not celecoxib or valdecoxib | MMP13, MMP11, MMP10 | RAB9A 2386/4885NPC1 2608/4885SMN1; SMN2 941/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.